Scientists test Two-Pronged immune attack on advanced cancers
NCT ID NCT07329894
Summary
This early-stage study is testing a new two-part treatment for advanced gastrointestinal cancers that have stopped responding to standard therapies. It combines a personalized cancer vaccine with an infusion of specially trained immune cells, both designed to target the patient's unique tumor. The main goal is to see if this combination is safe and tolerable, while also looking for early signs that it can shrink tumors or help patients live longer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Gobroad Hospital
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.